MX2009011467A - Combinaciones de eliminaciones de genes para cepas de vacuna de shigella atenuadas vivas. - Google Patents

Combinaciones de eliminaciones de genes para cepas de vacuna de shigella atenuadas vivas.

Info

Publication number
MX2009011467A
MX2009011467A MX2009011467A MX2009011467A MX2009011467A MX 2009011467 A MX2009011467 A MX 2009011467A MX 2009011467 A MX2009011467 A MX 2009011467A MX 2009011467 A MX2009011467 A MX 2009011467A MX 2009011467 A MX2009011467 A MX 2009011467A
Authority
MX
Mexico
Prior art keywords
vaccine strains
virg
sena
senb
msbb2
Prior art date
Application number
MX2009011467A
Other languages
English (en)
Inventor
Malabi M Venkatesan
Ryan T Ranallo
Shoshana Barnoy
Original Assignee
Us Sec The Army Walter Reed Ar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Sec The Army Walter Reed Ar filed Critical Us Sec The Army Walter Reed Ar
Publication of MX2009011467A publication Critical patent/MX2009011467A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Las cepas de vacuna de Shigella cuya caracter?stica atenuante primaria es la eliminaci?n del gen virG(icsA) y adicionalmente dos o m?s eliminaciones en los genes setAB(shET1), senA(shET2), senB(shET2-2), stxAB y msbB2. De esta forma, la cepa de vacuna tendr? tres o m?s eliminaciones en los genes identificados, ser?n m?s seguras, y reducir?n o eliminar?n los s?ntomas de fiebre y diarrea en humanos. Las siguientes cepas de vacunas espec?ficas han sido construidas: WRSS3 (?senA, ?senB, ?virG, ?msbB2), WRSf2G15 ?WirG, ?setAB, ?senA, ?senB, ?msbB2) y WRSd5 (?virG, ?stxAB, ?senA, ?senB, ?msbB2).
MX2009011467A 2007-04-25 2008-04-25 Combinaciones de eliminaciones de genes para cepas de vacuna de shigella atenuadas vivas. MX2009011467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90797407P 2007-04-25 2007-04-25
PCT/US2008/005342 WO2008133984A1 (en) 2007-04-25 2008-04-25 Combinations of gene deletions for live attenuated shigella vaccine strains

Publications (1)

Publication Number Publication Date
MX2009011467A true MX2009011467A (es) 2010-04-27

Family

ID=39725535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011467A MX2009011467A (es) 2007-04-25 2008-04-25 Combinaciones de eliminaciones de genes para cepas de vacuna de shigella atenuadas vivas.

Country Status (9)

Country Link
US (2) US8986708B2 (es)
EP (1) EP2150274B1 (es)
CN (1) CN101720229A (es)
AU (1) AU2008246150B2 (es)
BR (1) BRPI0816842A2 (es)
CA (1) CA2685132C (es)
MX (1) MX2009011467A (es)
RU (1) RU2467763C2 (es)
WO (1) WO2008133984A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2846062A1 (en) 2011-09-22 2013-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Shigella-derived vector and methods of using the same
CN108410790B (zh) * 2018-05-24 2019-05-14 中国人民解放军军事科学院军事医学研究院 ebgR基因敲除重组志贺氏菌的制备及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762941A (en) * 1988-07-15 1998-06-09 Institut Pasteur Modified shigella having reduced pathogenicity
AR242989A1 (es) * 1988-07-15 1993-06-30 Inst Pasteur I Nat De La Sante Metodo para modificar una cepa salvaje de una shigella entero-invasora para producir una cepa modificada apta para preparar una vacuna contra la cepa salvaje y cepa de shigella asi modificada.
SU1708351A1 (ru) * 1990-02-05 1992-01-30 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи Штамм бактерий SнIGеLLа SoNNeI используемый дл приготовлени живой вакцины против дизентерии Зонне
EP0441071B1 (en) * 1990-02-06 1994-09-21 Institut Pasteur Transformed shigella
US5468639A (en) * 1992-06-05 1995-11-21 University Of Maryland At Baltimore Isolated DNA molecule encoding ShET2 of Shigella flexneri 2a
US5589380A (en) * 1992-06-05 1996-12-31 University Of Maryland At Baltimore Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a
US6759241B1 (en) * 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist

Also Published As

Publication number Publication date
US9320789B2 (en) 2016-04-26
AU2008246150B2 (en) 2013-07-25
EP2150274A1 (en) 2010-02-10
RU2467763C2 (ru) 2012-11-27
WO2008133984A1 (en) 2008-11-06
US8986708B2 (en) 2015-03-24
CA2685132C (en) 2016-11-08
WO2008133984A4 (en) 2009-03-05
RU2009143526A (ru) 2011-05-27
US20150165012A1 (en) 2015-06-18
US20080267998A1 (en) 2008-10-30
AU2008246150A1 (en) 2008-11-06
CA2685132A1 (en) 2008-11-06
CN101720229A (zh) 2010-06-02
BRPI0816842A2 (pt) 2019-09-24
EP2150274B1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
MX2021000285A (es) Composiciones que comprenden cepas bacterianas.
UA98506C2 (en) Attenuated mycoplasma gallisepticum strains
MX2010003719A (es) Vacuna de mycoplasma bovis y metodos de uso de la misma.
MX2021010918A (es) Composiciones y metodos para tratar la mucopolisacaridosis tipo i.
MX2011012347A (es) Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.
MX2021009001A (es) Composiciones microbianas para alimentacion directa y sus metodos de uso.
ME01156B (me) Postupci i kompozicije za imunizaciju svinja protiv svinjskog cirkovirusa
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MX2023000736A (es) Productos microbianos alimentados en directo.
AR093061A1 (es) Metodos y composiciones para el tratamiento y control de enfermedades en las plantas
BRPI0821240B8 (pt) formas mutantes de estreptolisina o
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
WO2007053489A3 (en) Attenuated salmonella enterica serovar paratyphi a and uses thereof
PE20090446A1 (es) Plasmidos para transformar una bacteria del genero acidithiobacillus spp. y metodo de transformacion
PH12020552291A1 (en) System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host
MX2009011467A (es) Combinaciones de eliminaciones de genes para cepas de vacuna de shigella atenuadas vivas.
WO2010101750A3 (en) Attenuated salmonella enterica serovar paratyphi a and uses thereof
GB2458057A (en) Francisella strain for live vaccine
NZ589981A (en) Cattle vaccines comprising a disrupted M. bovis bacterium
CO2019012289A2 (es) Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar
MXPA05008774A (es) Cepas atenuadas de vibrio cholerae mejoradas en su seguridad ambiental presentadas en forma liofilizada para la vacunacion por via oral.
WO2011011725A3 (en) Use of toxoplasma and derived compositions to prevent or treat microbial infections
WO2008044149A8 (en) Shigella ipad protein and its use as a vaccine against shigella infection
MX360831B (es) Virus de influenza c y vacuna.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal